STOCKHOLM, Sweden, April 30, 2013 – The nomination committee for Karo Bio AB (publ) today informed the company about its proposals to the annual general meeting.

Ahead of the annual general meeting 2013, the nomination committee has consisted of Göran Wessman, chairman of the board, representing Mikael Lönn and his own holding (Protem Wessman AB), Jan Lundström, representing Johan Claesson and his own holding, Lars Magnusson, representing Johan Edlund and his own holding, Per-Anders Johansson, representing his own holding (Nomic AB), and Thomas Andersson, representing Farstorps Gård AB. Jan Lundström was elected chairman of the nomination committee.

The nomination committee proposes re-election of board members Göran Wessman, Christer Fåhraeus, Per-Anders Johansson and Anders Waas and new election of Sibylle Lenz. Göran Wessman is proposed to be re-elected as chairman of the board. The proposal entails that Per Bengtsson, the company’s CEO, shall no longer form part of the board, for the purpose of focusing the roles within the company.

Sibylle Lenz was born in 1961 and holds a PhD in Medicinal Chemistry from the Faculty of Pharmacy at Copenhagen University. She is CEO of Alligator Bioscience AB since August 2010. Previously, Sibylle Lenz worked as Vice President, Corporate Business Development at Dako A/S between 2008 and 2010, and before that she had several senior positions within both research and development and commercial areas in H. Lundbeck A/S.

The nomination committee has assessed that the fees to the board (including fees for committee work) should remain unchanged and amount to SEK 420,000 to the chairman of the board and SEK 150,000 to each of the other board members.

Further, the nomination committee proposes re-election of PwC as auditor and that fee to the auditor shall be paid as per approved invoice.

Madeleine Rydberger, advocate, is proposed as chairman of the general meeting.

Last, the nomination committee proposes unchanged principles for the nomination committee, with the adjustment that the principles shall remain in force until otherwise resolved.

The nomination committee’s motivated statement regarding its proposals will be published on the company’s website as soon as it has been received by the company.

For further information, please contact:
Göran Wessman, Chairman of Karo Bio AB, mobile +46 708 161 450 or via

About Karo Bio
Karo Bio is a pharmaceutical company focused on the research and development of innovative drugs for large medical needs. The company runs a number of drug development projects within the indication areas neuropsychiatry, inflammation, autoimmune diseases and cancer. An important foundation for the company’s activities is its unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals, as well as related mechanisms of action. Karo Bio is based in Huddinge, Sweden, has around 43 employees and is listed on NASDAQ OMX Stockholm.

This press release is also available at and


About Us

Karo Pharma is a specialty pharma company that develops and markets products to pharmacies and directly to healthcare providers. The share is listed on Nasdaq Stockholm in the Mid Cap segment.


Documents & Links